PROSPERS

• Research type

  Research Study

• Full title

  PROSPERS: An international observational programme of research in ultra-rare sarcomas, comprising multiple retrospective and prospective sub-studies

• IRAS ID

  364960

• Contact name

  Andrea Napolitano

• Contact email

  Andrea.Napolitano@rmh.nhs.uk

• Sponsor organisation

  Istituto Nazionale dei Tumori

• Duration of Study in the UK

  5 years, 0 months, 1 days

• Research summary

  PROSPERS is an international research programme designed to improve understanding and outcomes for patients diagnosed with ultra-rare sarcomas. Because these cancers are very uncommon, individual hospitals usually see only small numbers of patients, making it difficult to study how best to treat them.

  The aim of PROSPERS is to bring together information from many local centres worldwide to improve knowledge, guide future research, and support the development of better treatments for people with ultra-rare sarcomas.

  The PROSPERS programme includes both retrospective and prospective sub-studies, each focusing on specific ultra-rare sarcoma subtypes.

  - Retrospective sub-studies will collect and analyse information that has been recorded during routine clinical care.
  - Prospective sub-studies will collect clinical information during routine care and continue to collect follow-up data over time. These studies will not involve any experimental treatments, and no additional hospital visits will be required beyond standard care.

  The information collected may include details such as diagnosis, treatments received, side effects, and outcomes, including survival and quality of life where available. Each participating hospital will identify eligible patients from their own records. Any data shared outside the hospital will be coded so that individuals cannot be directly identified.

  For prospective sub-studies, patients will be asked to give consent for their information to be used and for follow-up data to be collected during their treatment and care.
  For retrospective sub-studies, consent will not usually be required, as only routine clinical information already held by local centres will be used.

• REC name

  North West - Liverpool Central Research Ethics Committee

• REC reference

  26/NW/0132

• Date of REC Opinion

  13 May 2026

• REC opinion

  Favourable Opinion